share_log

Oppenheimer Adjusts Intellia Therapeutics' Price Target to $130 From $160, Maintains Outperform Rating

Oppenheimer Adjusts Intellia Therapeutics' Price Target to $130 From $160, Maintains Outperform Rating

奧本海默將Intellia治療公司的目標價從160美元調整為130美元,保持優於大盤的評級
MT Newswires ·  2022/05/09 09:18

Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論